Shanghai SIMR Biotechnology Co.,Ltd

中文 | EN

中文 EN

Expanded Access Policy Press Releases

Home > MEDIA

MEDIA

Expanded Access Policy

12 2022-11

Shanghai SIMR Biotech received 150 million Chinese Yuan C1 r

On November 8, 2022, Shanghai SIMR Biotech (here in after referred to as "SIMR Bio " or the "Company") announced that it has obtained a C1 round of financing of 150 million Chinese...
13 2022-05

Expanded Access Policy for SR419

At SIMR we aspire to discover and develop differentiated therapeutics for the treatment of peripheral neuropathic pain. SIMR’s lead product, SR419, is a candidate drug with novel mechanism of action f...
17 2021-12

Milestone of SIMR —— The first Phase II clinical study for S

On 17th Dec 2021, Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company”) announced that company’s investigational drug SR419, the first asset of SIMR e...
01 2021-11

Milestone - SR1375'S Phase II Clinical Trial Approved by the

Shanghai, China, Nov 1,2021 ---- Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company") initiated the first-in-human study of candidate drug SR750...
11 2021-10

Milestone|| Dosing of the first cohort successfully complete

Shanghai, China, October 11, 2021 ---- Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" o...
20 2020-09

The first patient successfully dosed with the candidate drug

Shanghai, China, September 18, 2020. Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or &q...

Home Previous 1 2 3 4 Next Last

Previous Next Road 4 page 19 strip